Elsholtzia ciliata essential oil extract as antiarrhythmic drug (WO2019193400 A1)

Abstract

The main objective of the present invention is to provide a new formulation which comprises Elsholtzia ciliata Extract. Experiments have shown that ECE decreases the rate of depolarization of upstroke of myocardial action potential, slows the propagation of electrical excitation and distributes the ECG QRS range, i.e. treats the heart as a first-class anti-arrhythmic drug. Due to its herbal origin, the ECE can be well tolerated and widely used as a safe drug for eliminating cardiac arrhythmias. The main objective of the present invention is to provide a new formulation which comprises a herbal extract composition comprising aromatic aniseed grass essential oil which has been prepared from Elsholtzia cilliata herb.; emulsifier tween 20; and purified water. According to this main object, formulations according to the present invention are suitable for treatment, prevention of for use in the treatment or prevention of cardiac arrhythmic disease, wherein said cardiac arrhythmic disease is cardiac tachycardia which is related with the extrasystoles formed in the ventricles, as well as tachycardia due to the circulation of the pulse in the ventricles. The herbal extract composition comprises 10-80 mL of aromatic aniseed grass essential oil, 10-80 ml emulsifier Tween 20 and 20-80 mL purified water. The herbal extract composition is prepared as pharmaceutical formulation or medicinal product in the form of emulsion, tablet or capsule. Another object of the present invention is to provide a method by which special first-class anti-arythmic drug is produced. A method for preparing the herbal extract composition is as follows: extracting dried leaves of Elsholtzia cilliata herb by hydrodistillation. Mixing an amount of 10-80 ml of said Elsholtzia cilliata oil extraxt with 10-80 ml emulsifier Tween 20. After thoroughly mixing 20-80 mL pure water are added and again mixing. Many antiarrhythmics are used in clinical practice. ECE La présente invention concerne une nouvelle formulation qui comprend de l’extrait d’Elsholtzia ciliata. Les expérimentations ont montré qu’ECE fait baisser le taux de dépolarisation de la course ascendante du potentiel d’action myocardique, ralentit la propagation de l’excitation électrique et distribue la plage ECG QRS, c’est-à-dire traite le cœur comme médicament antiarythmique de première classe. Dû à son origine végétale, l’ECE peut être bien toléré et largement utilisé comme médicament sûr pour l’élimination des arythmies cardiaques.